| Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study RM Grant, PL Anderson, V McMahan, A Liu, KR Amico, M Mehrotra, ... The Lancet infectious diseases 14 (9), 820-829, 2014 | 1289 | 2014 |
| Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men PL Anderson, DV Glidden, A Liu, S Buchbinder, JR Lama, JV Guanira, ... Science translational medicine 4 (151), 151ra125-151ra125, 2012 | 1069 | 2012 |
| HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial MB Deutsch, DV Glidden, J Sevelius, J Keatley, V McMahan, J Guanira, ... The lancet HIV 2 (12), e512-e519, 2015 | 291 | 2015 |
| Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial MM Solomon, KH Mayer, DV Glidden, AY Liu, VM McMahan, JV Guanira, ... Clinical Infectious Diseases 59 (7), 1020-1026, 2014 | 200 | 2014 |
| Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial K Mulligan, DV Glidden, PL Anderson, A Liu, V McMahan, P Gonzales, ... Clinical infectious diseases 61 (4), 572-580, 2015 | 190 | 2015 |
| Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis MM Solomon, JR Lama, DV Glidden, K Mulligan, V McMahan, AY Liu, ... Aids 28 (6), 851-859, 2014 | 181 | 2014 |
| HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial SP Buchbinder, DV Glidden, AY Liu, V McMahan, JV Guanira, KH Mayer, ... The Lancet infectious diseases 14 (6), 468-475, 2014 | 166 | 2014 |
| Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru JR Lama, A Lucchetti, L Suarez, VA Laguna-Torres, JV Guanira, M Pun, ... The Journal of infectious diseases 194 (10), 1459-1466, 2006 | 130 | 2006 |
| Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection KR Amico, JL Marcus, V McMahan, A Liu, KA Koester, P Goicochea, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 66 (5), 530-537, 2014 | 102 | 2014 |
| HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial T Liegler, M Abdel-Mohsen, LG Bentley, R Atchison, T Schmidt, J Javier, ... The Journal of infectious diseases 210 (8), 1217-1227, 2014 | 95 | 2014 |
| Strong correlation between concentrations of tenofovir (TFV) emtricitabine (FTC) in hair and TFV diphosphate and FTC triphosphate in dried blood spots in the iPrEx open label … M Gandhi, iPrEx Study Team, DV Glidden, iPrEx Study Team, A Liu, ... The Journal of infectious diseases 212 (9), 1402-1406, 2015 | 79 | 2015 |
| Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study M Gandhi, DV Glidden, K Mayer, M Schechter, S Buchbinder, B Grinsztejn, ... The lancet HIV 3 (11), e521-e528, 2016 | 77 | 2016 |
| Symptoms, side effects and adherence in the iPrEx open-label extension DV Glidden, KR Amico, AY Liu, SG Hosek, PL Anderson, SP Buchbinder, ... Clinical Infectious Diseases 62 (9), 1172-1177, 2016 | 72 | 2016 |
| Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine DV Glidden, K Mulligan, V McMahan, PL Anderson, J Guanira, ... Clinical Infectious Diseases 67 (3), 411-419, 2018 | 70 | 2018 |
| Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world SA Safren, ES Hendriksen, L Smeaton, DD Celentano, MC Hosseinipour, ... AIDS and Behavior 16, 266-277, 2012 | 70 | 2012 |
| Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America G Ravasi, B Grinsztejn, R Baruch, JV Guanira, R Luque, CF Cáceres, ... Journal of the International AIDS Society 19, 21113, 2016 | 58 | 2016 |
| Transgender women in clinical trials of pre-exposure prophylaxis RM Grant, JM Sevelius, JV Guanira, JV Aguilar, S Chariyalertsak, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 72, S226-S229, 2016 | 49 | 2016 |
| Self-reported recent PrEP dosing and drug detection in an open label PrEP study KR Amico, M Mehrotra, VI Avelino-Silva, V McMahan, VG Veloso, ... AIDS and Behavior 20, 1535-1540, 2016 | 44 | 2016 |
| The safety of tenofovir–emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B MM Solomon, M Schechter, AY Liu, VM McManhan, JV Guanira, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 71 (3), 281-286, 2016 | 42 | 2016 |
| Brief report: Recovery of bone mineral density after discontinuation of tenofovir-based HIV pre-exposure prophylaxis DV Glidden, K Mulligan, V McMahan, PL Anderson, J Guanira, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 76 (2), 177-182, 2017 | 41 | 2017 |
Dave GliddenProfessor of Biostatistics, UC San FranciscoVerified email at ucsf.edu
